The company reported positive trial data for its lead therapy to treat two different eye conditions.
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
/PRNewswire/ -- The Global Dry Eye Syndrome market is witnessing continued growth due to the factors such as the growing demand for effective treatments, the...
June S&P 500 futures (ESM23) are trending up +0.07% this morning after three major U.S. benchmark indices finished the regular session in the red as investors assessed a mixed slate of corporate earnings...
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...
EyePoint Pharmaceuticals (EYPT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against EyePoint Pharmaceuticals ("Eyepoint" or...